

# Non-small cell lung cancer – crizotinib or entrectinib – initial authority application

## Online PBS Authorities



Requesting PBS Authorities online provides an immediate assessment in real time.

For more information and how to access the **Online PBS Authorities** system, go to [servicesaustralia.gov.au/hppbsauthorities](https://servicesaustralia.gov.au/hppbsauthorities)

## When to use this form

Use this form to apply for **initial** PBS-subsidised crizotinib or entrectinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

## Important information

**Initial** applications to start PBS-subsidised treatment can be made in real time using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for NSCLC **initial** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

## Continuing treatment

This form is **ONLY** for **initial** treatment.

After an authority application for initial treatment has been approved, applications for **continuing** treatment can be made in real time using the **Online PBS Authorities** system or by phone.

Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

## Treatment specifics

Patients must have evidence of gene rearrangement identified by either:

- fluorescence in situ hybridisation (FISH) testing, or
- positive next generation sequencing (NGS) testing.

## For more information

Go to [servicesaustralia.gov.au/healthprofessionals](https://servicesaustralia.gov.au/healthprofessionals)



# Non-small cell lung cancer – crizotinib or entrectinib – initial authority application

## Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

Go to [servicesaustralia.gov.au/hppbsauthorities](http://servicesaustralia.gov.au/hppbsauthorities)

## Patient's details

### 1 Medicare card number

Ref no.

**or**

Department of Veterans' Affairs card number

### 2 Dr Mr Mrs Miss Ms Other

Family name

First given name

### 3 Date of birth (DD MM YYYY)

## Prescriber's details

### 4 Prescriber number

### 5 Dr Mr Mrs Miss Ms Other

Family name

First given name

### 6 Business phone number (including area code)

Alternative phone number (including area code)

## Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

- 7** Does the patient have non-squamous type non-small cell lung cancer (NSCLC) or not otherwise specified type NSCLC?  
Yes   
No
- 8** Is the patient's World Health Organization (WHO) performance status 2 or less?  
Yes   
No
- 9** Is this treatment the sole PBS-subsidised systemic anti-cancer therapy for this condition?  
Yes   
No
- 10** This application is for:  
 crizotinib ▶ *Go to 11*  
**or**  
 entrectinib ▶ *Go to 12*
- 11** The patient has evidence of:  
 anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material ▶ *Go to 14*  
**or**  
 c-ROS proto-oncogene 1 (ROS1) gene rearrangement in tumour material ▶ *Go to 13*
- 12** Does the patient have evidence of c-ROS proto-oncogene 1 (ROS1) gene rearrangement in tumour material?  
Yes   
No
- 13** The patient has:  
 not received prior treatment with a ROS1 receptor tyrosine kinase inhibitor for this condition  
**or**  
 developed intolerance to a ROS1 receptor tyrosine kinase inhibitor necessitating permanent treatment withdrawal.
- 14** The patient's gene rearrangement has been identified by:  
 fluorescence in situ hybridisation (FISH) testing of at least 15% positive cells  
**or**  
 positive next generation sequencing (NGS) testing



MCA0PB156 2409

## Checklist

- 15  The relevant attachments need to be provided with this form.

Details of the proposed prescription(s).

## Privacy notice

- 16 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application.

Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at [servicesaustralia.gov.au/privacypolicy](https://servicesaustralia.gov.au/privacypolicy)

## Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at [servicesaustralia.gov.au/hpos](https://servicesaustralia.gov.au/hpos)

### 17 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine.
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application.
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.
- the information I have provided in this form is complete and correct.

### I understand that:


- giving false or misleading information is a serious offence.

I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)


---

## Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at [servicesaustralia.gov.au/hpos](https://servicesaustralia.gov.au/hpos)

**or**

- by post (signature required) to

Services Australia  
Complex Drugs Programs  
Reply Paid 9826  
HOBART TAS 7001